Clin Transl Oncol. 2009 Nov;11(11):727-36.
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.
Alberola Candel V,
Carrato Mena A,
DĂ*az-Rubio GarcĂ*a E,
GascĂłn Vilaplana P,
González Barón M,
MartĂ*n JimĂ©nez M,
Alba Conejo E,
Cassinello Espinosa J,
Colomer R,
Cruz Hernández JJ,
Barnadas I Molins A,
Camps Herrero C,
Casas Fernández de Tejerina AM,
Carulla Torrent J,
Constenla Figueiras M,
Gavilá Gregori J,
Isla Casado MD,
Massuti Sureda B,
Provencio Pulla M,
RodrĂ*guez Sánchez CA,
Sanz Ortiz J.
Servicio de OncologĂ*a MĂ©dica, Hospital Arnau de Vilanova, Valencia, Spain.
Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.
PMID: 19917536 [PubMed - in process